Delta Cure - 3nd International Meeting | Milan, October 11-12, 2024

Main Topics

On this page you will find the Main Topics of the 3rd Delta Cure...

Virology, Pathogenesis and Epidemiology The HDV virus: latest insights Pathogenesis of HDV: the virologist point of view Pathogenesis of HDV: the immunologist point of view Epidemiology of HDV: to be revisited? Diagnosis and Endpoints Diagnosis of HDV: HDV RNA quantification and new HBV biomarkers Diagnosis of HDV: Fibroscan and other non-invasive markers Immunology of HDV in untreated and treated patients Endpoints of HDV therapy Current and new antiviral treatments PegIFN monotherapy: efficacy and safety and clinical outcomes Bulevirtide monotherapy: efficacy and safety Bulevirtide combined with interferon: efficacy and safety Bulevirtide: clinical outcomes and survival Lonafarnib with or without peg-interferon lambda New anti-HDV drugs

Virology, Pathogenesis and Epidemiology The HDV virus: latest insights Pathogenesis of HDV: the virologist point of view Pathogenesis of HDV: the immunologist point of view Epidemiology of HDV: to be revisited? Diagnosis and Endpoints Diagnosis of HDV: HDV RNA quantification and new HBV biomarkers Diagnosis of HDV: Fibroscan and other non-invasive markers Immunology of HDV in untreated and treated patients Endpoints of HDV therapy Current and new antiviral treatments PegIFN monotherapy: efficacy and safety and clinical outcomes Bulevirtide monotherapy: efficacy and safety Bulevirtide combined with interferon: efficacy and safety Bulevirtide: clinical outcomes and survival Lonafarnib with or without peg-interferon lambda New anti-HDV drugs

Virology, Pathogenesis and Epidemiology The HDV virus: latest insights Pathogenesis of HDV: the virologist point of view Pathogenesis of HDV: the immunologist point of view Epidemiology of HDV: to be revisited? Diagnosis and Endpoints Diagnosis of HDV: HDV RNA quantification and new HBV biomarkers Diagnosis of HDV: Fibroscan and other non-invasive markers Immunology of HDV in untreated and treated patients Endpoints of HDV therapy Current and new antiviral treatments PegIFN monotherapy: efficacy and safety and clinical outcomes Bulevirtide monotherapy: efficacy and safety Bulevirtide combined with interferon: efficacy and safety Bulevirtide: clinical outcomes and survival Lonafarnib with or without peg-interferon lambda New anti-HDV drugs

Virology, Pathogenesis and Epidemiology

  • The HDV virus: latest insights
  • Pathogenesis of HDV: the virologist point of view
  • Pathogenesis of HDV: the immunologist point of view
  • Epidemiology of HDV: to be revisited?

Diagnosis and Endpoints

  • Diagnosis of HDV: HDV RNA quantification and new HBV biomarkers
  • Diagnosis of HDV: Fibroscan and other non-invasive markers
  • Immunology of HDV in untreated and treated patients
  • Endpoints of HDV therapy

Current and new antiviral treatments

  • PegIFN monotherapy: efficacy and safety and clinical outcomes
  • Bulevirtide monotherapy: efficacy and safety
  • Bulevirtide combined with interferon: efficacy and safety
  • Bulevirtide: clinical outcomes and survival
  • Lonafarnib with or without peg-interferon lambda
  • New anti-HDV drugs
×

Icon